US5144011A
(en)
*
|
1981-06-26 |
1992-09-01 |
Boston University |
Acidity-sensitive spacer molecule to control the release of pharmaceuticals from molecular carriers
|
GB8334499D0
(en)
*
|
1983-12-24 |
1984-02-01 |
Beecham Group Plc |
Derivatives
|
US4764368A
(en)
*
|
1984-08-29 |
1988-08-16 |
Dana-Farber Cancer Institute, Inc. |
Acid-cleavable compound
|
GB8430252D0
(en)
*
|
1984-11-30 |
1985-01-09 |
Beecham Group Plc |
Compounds
|
US4889916A
(en)
*
|
1985-11-19 |
1989-12-26 |
The Johns Hopkins University |
Protein label and drug delivery system
|
US4751286A
(en)
*
|
1985-11-19 |
1988-06-14 |
The Johns Hopkins University |
Protein label and drug delivery system
|
US4997913A
(en)
*
|
1986-06-30 |
1991-03-05 |
Oncogen |
pH-sensitive immunoconjugates and methods for their use in tumor therapy
|
US5141739A
(en)
*
|
1986-07-03 |
1992-08-25 |
Advanced Magnetics, Inc. |
Delivery of x-ray contrast agents using receptor mediated endocytosis
|
US5449759A
(en)
*
|
1987-05-16 |
1995-09-12 |
Somatogen, Inc. |
Hemoglobins with intersubunit desulfide bonds
|
US4981979A
(en)
*
|
1987-09-10 |
1991-01-01 |
Neorx Corporation |
Immunoconjugates joined by thioether bonds having reduced toxicity and improved selectivity
|
US5017693A
(en)
*
|
1987-12-02 |
1991-05-21 |
Neorx Corporation |
Methods for introducing a sulfhydryl amino or hydroxyl groups to a compound
|
EP0318948B1
(de)
*
|
1987-12-02 |
1992-08-19 |
Neorx Corporation |
Spaltbare Immun-Conjugate für die Abgabe und Freisetzung von Agenzien in natürlicher Form
|
US5563250A
(en)
*
|
1987-12-02 |
1996-10-08 |
Neorx Corporation |
Cleavable conjugates for the delivery and release of agents in native form
|
US5141648A
(en)
*
|
1987-12-02 |
1992-08-25 |
Neorx Corporation |
Methods for isolating compounds using cleavable linker bound matrices
|
IL89220A
(en)
*
|
1988-02-11 |
1994-02-27 |
Bristol Myers Squibb Co |
Immunoconjugates of anthracycline, their production and pharmaceutical preparations containing them
|
US5057301A
(en)
*
|
1988-04-06 |
1991-10-15 |
Neorx Corporation |
Modified cellular substrates used as linkers for increased cell retention of diagnostic and therapeutic agents
|
US5066490A
(en)
*
|
1988-06-01 |
1991-11-19 |
The United States Of America As Represented By The Secretary Of The Department Of Health & Human Services |
Protein crosslinking reagents cleavable within acidified intracellular vesicles
|
US5601819A
(en)
*
|
1988-08-11 |
1997-02-11 |
The General Hospital Corporation |
Bispecific antibodies for selective immune regulation and for selective immune cell binding
|
US5171563A
(en)
*
|
1988-09-30 |
1992-12-15 |
Neorx Corporation |
Cleavable linkers for the reduction of non-target organ retention of immunoconjugates
|
US5063109A
(en)
*
|
1988-10-11 |
1991-11-05 |
Abbott Laboratories |
Covalent attachment of antibodies and antigens to solid phases using extended length heterobifunctional coupling agents
|
US5545727A
(en)
|
1989-05-10 |
1996-08-13 |
Somatogen, Inc. |
DNA encoding fused di-alpha globins and production of pseudotetrameric hemoglobin
|
WO1990014844A2
(en)
*
|
1989-06-06 |
1990-12-13 |
Neorx Corporation |
Sugars as cleavable linkers for the delivery and release of agents in native form
|
US5527527A
(en)
*
|
1989-09-07 |
1996-06-18 |
Alkermes, Inc. |
Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
|
US5154924A
(en)
*
|
1989-09-07 |
1992-10-13 |
Alkermes, Inc. |
Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
|
US5182107A
(en)
*
|
1989-09-07 |
1993-01-26 |
Alkermes, Inc. |
Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
|
US5977307A
(en)
*
|
1989-09-07 |
1999-11-02 |
Alkermes, Inc. |
Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins
|
US6329508B1
(en)
|
1989-09-07 |
2001-12-11 |
Alkermes, Inc. |
Transferrin receptor reactive chimeric antibodies
|
US5672683A
(en)
*
|
1989-09-07 |
1997-09-30 |
Alkermes, Inc. |
Transferrin neuropharmaceutical agent fusion protein
|
US5140013A
(en)
*
|
1989-11-28 |
1992-08-18 |
Universite Laval |
Maleic anhydride derivatives used as conjugation agents of anti-tumor agents on desired carriers
|
CA2075927A1
(en)
|
1990-02-16 |
1991-08-17 |
Victor A. Raso |
Hybrid reagents capable of selectively releasing molecules into cells
|
US5466681A
(en)
*
|
1990-02-23 |
1995-11-14 |
Microcarb, Inc. |
Receptor conjugates for targeting penicillin antibiotics to bacteria
|
US5874549A
(en)
*
|
1990-09-28 |
1999-02-23 |
Neorx Corporation |
Acid-cleavable compound
|
JPH04334377A
(ja)
*
|
1990-12-31 |
1992-11-20 |
Akzo Nv |
酸−不安定性リンカー分子
|
US5242680A
(en)
*
|
1991-08-23 |
1993-09-07 |
Merck & Co., Inc. |
Thiol-reactive maleimido-based radiolabeling reagents
|
DE69226197T2
(de)
*
|
1991-11-08 |
1999-02-11 |
Somatogen Inc |
Hämoglobine als arzneimittelabgabesystem
|
WO1993013768A1
(en)
*
|
1992-01-06 |
1993-07-22 |
Ariad Pharmaceuticals, Inc. |
Therapeutic uses of thiol-oxidizing agents and sulfhydryl-alkylating agents
|
US5505931A
(en)
*
|
1993-03-04 |
1996-04-09 |
The Dow Chemical Company |
Acid cleavable compounds, their preparation and use as bifunctional acid-labile crosslinking agents
|
EP0602290B1
(de)
*
|
1992-12-04 |
1999-08-25 |
ConjuChem, Inc. |
Antikörper-konjugiertes-Hepatitis B-Oberflächenantigen und dessen Verwendung
|
US5612474A
(en)
*
|
1994-06-30 |
1997-03-18 |
Eli Lilly And Company |
Acid labile immunoconjugate intermediates
|
US6015555A
(en)
*
|
1995-05-19 |
2000-01-18 |
Alkermes, Inc. |
Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
|
US5830478A
(en)
*
|
1995-06-07 |
1998-11-03 |
Boston Biomedical Research Institute |
Method for delivering functional domains of diphtheria toxin to a cellular target
|
EP0873363B1
(de)
|
1995-06-14 |
2010-10-06 |
The Regents of The University of California |
Hochaffine humane antikörper gegen tumorantigene
|
US8217015B2
(en)
*
|
2003-04-04 |
2012-07-10 |
Arrowhead Madison Inc. |
Endosomolytic polymers
|
ES2195036T3
(es)
*
|
1995-12-22 |
2003-12-01 |
Bristol Myers Squibb Co |
Conectores de hidrazona ramificados.
|
US6261562B1
(en)
|
1997-02-25 |
2001-07-17 |
Corixa Corporation |
Compounds for immunotherapy of prostate cancer and methods for their use
|
US6960457B1
(en)
*
|
1997-09-04 |
2005-11-01 |
Stanford University |
Reversible immobilization of arginine-tagged moieties on a silicate surface
|
CA2310805A1
(en)
|
1997-11-24 |
1999-06-03 |
Johnson T. Wong |
Methods for treatment of hiv or other infections using a t cell or viral activator and anti-retroviral combination therapy
|
EP1042360A2
(de)
|
1997-12-24 |
2000-10-11 |
Corixa Corporation |
Zusammensetzungen für immunotherapie und diagnose von brustkrebs und verfahren für ihre verwendung
|
AR020318A1
(es)
|
1998-03-18 |
2002-05-08 |
Corixa Corp |
Una molecula polinucleotidica aislada, un polipeptido aislado codificado por dicha molecula, un vector de expresion, una celula huesped transformada, unaproteina de fusion, una composicion farmaceutica y una vacuna que comprenden dicho polipeptido o proteina; metodos para el tratamiento, deteccion,
|
US20020147143A1
(en)
|
1998-03-18 |
2002-10-10 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of lung cancer
|
US6869604B1
(en)
*
|
1998-03-27 |
2005-03-22 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Recombinant anti-tumor RNAse
|
US7157418B1
(en)
|
1998-07-22 |
2007-01-02 |
Osprey Pharmaceuticals, Ltd. |
Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders
|
US20030215421A1
(en)
*
|
1999-07-21 |
2003-11-20 |
Mcdonald John R. |
Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders
|
US20030235557A1
(en)
|
1998-09-30 |
2003-12-25 |
Corixa Corporation |
Compositions and methods for WT1 specific immunotherapy
|
US6652836B2
(en)
|
1998-10-15 |
2003-11-25 |
Fluoroprobe, Inc. |
Method for viewing tumor tissue located within a body cavity
|
US6299860B1
(en)
*
|
1998-10-15 |
2001-10-09 |
Fluoro Probe, Inc. |
Method for viewing diseased tissue located within a body cavity
|
AU769293B2
(en)
|
1998-12-08 |
2004-01-22 |
Corixa Corporation |
Compounds and methods for treatment and diagnosis of chlamydial infection
|
TWI242000B
(en)
|
1998-12-10 |
2005-10-21 |
Univ Southern California |
Reversible aqueous pH sensitive lipidizing reagents, compositions and methods of use
|
US20020119158A1
(en)
|
1998-12-17 |
2002-08-29 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of ovarian cancer
|
US6579973B1
(en)
|
1998-12-28 |
2003-06-17 |
Corixa Corporation |
Compositions for the treatment and diagnosis of breast cancer and methods for their use
|
ATE399793T1
(de)
|
1999-04-02 |
2008-07-15 |
Corixa Corp |
Verbindungen und verfahren für therapie und diagnose von lungenkrebs
|
US20040146516A1
(en)
*
|
1999-06-17 |
2004-07-29 |
Utah Ventures Ii L.P. |
Lumen-exposed molecules and methods for targeted delivery
|
AU2001227679A1
(en)
*
|
2000-02-25 |
2001-09-03 |
General Atomics |
Mutant nucleic binding enzymes and use thereof in diagnostic, detection and purification methods
|
US20040002068A1
(en)
|
2000-03-01 |
2004-01-01 |
Corixa Corporation |
Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
|
AU2001250898A1
(en)
*
|
2000-03-17 |
2001-10-03 |
The Salk Institute For Biological Studies |
Compositions associated with complex formation
|
US6610504B1
(en)
|
2000-04-10 |
2003-08-26 |
General Atomics |
Methods of determining SAM-dependent methyltransferase activity using a mutant SAH hydrolase
|
WO2002000174A2
(en)
|
2000-06-28 |
2002-01-03 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of lung cancer
|
ATE536550T1
(de)
|
2000-10-06 |
2011-12-15 |
Life Technologies Corp |
Halbleiter nanokristalle enthaltende transfektibare mizellen
|
US20050059031A1
(en)
|
2000-10-06 |
2005-03-17 |
Quantum Dot Corporation |
Method for enhancing transport of semiconductor nanocrystals across biological membranes
|
US7045283B2
(en)
|
2000-10-18 |
2006-05-16 |
The Regents Of The University Of California |
Methods of high-throughput screening for internalizing antibodies
|
US7378280B2
(en)
|
2000-11-16 |
2008-05-27 |
California Institute Of Technology |
Apparatus and methods for conducting assays and high throughput screening
|
WO2002089747A2
(en)
|
2001-05-09 |
2002-11-14 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of prostate cancer
|
EP1406493A4
(de)
*
|
2001-06-11 |
2006-06-14 |
Xenoport Inc |
Verabreichung von mitteln über den pept-2-transporter
|
WO2003048295A1
(en)
|
2001-11-30 |
2003-06-12 |
Fluidigm Corporation |
Microfluidic device and methods of using same
|
AU2002365279B2
(en)
|
2001-12-17 |
2009-08-13 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of inflammatory bowel disease
|
US20030158254A1
(en)
*
|
2002-01-24 |
2003-08-21 |
Xenoport, Inc. |
Engineering absorption of therapeutic compounds via colonic transporters
|
US20030158089A1
(en)
*
|
2002-01-24 |
2003-08-21 |
Xenoport, Inc. |
Administrative agents via the SMVT transporter
|
CA2478924A1
(en)
*
|
2002-03-14 |
2003-09-18 |
Qlt Inc. |
Cancer associated araf1 protein kinase and its uses
|
US7332585B2
(en)
|
2002-04-05 |
2008-02-19 |
The Regents Of The California University |
Bispecific single chain Fv antibody molecules and methods of use thereof
|
US6756397B2
(en)
|
2002-04-05 |
2004-06-29 |
Immunogen, Inc. |
Prodrugs of CC-1065 analogs
|
US20030228619A1
(en)
*
|
2002-06-10 |
2003-12-11 |
Xenoport, Inc. |
Peptide nucleic acids as tags in encoded libraries
|
KR20050038005A
(ko)
|
2002-07-18 |
2005-04-25 |
헬릭스 바이오파마 코포레이션 |
암세포 성장의 저해를 위한 우레아제의 사용
|
US7390898B2
(en)
|
2002-08-02 |
2008-06-24 |
Immunogen Inc. |
Cytotoxic agents containing novel potent taxanes and their therapeutic use
|
EP1852441B1
(de)
|
2002-09-24 |
2012-03-28 |
The Burnham Institute |
Mittel zur Modulierung der EPH-Rezeptor-Aktivität
|
US20050059025A1
(en)
*
|
2002-10-07 |
2005-03-17 |
Five Giralda Farms |
Compositions, organisms and methodologies employing a novel human kinase
|
US20040161424A1
(en)
*
|
2002-10-08 |
2004-08-19 |
Xenoport |
Human organic solute transporters
|
WO2004032878A2
(en)
*
|
2002-10-10 |
2004-04-22 |
Wyeth |
Compositions, organisms and methodologies employing a novel human kinase
|
US7122361B2
(en)
*
|
2002-10-10 |
2006-10-17 |
Wyeth |
Compositions employing a novel human kinase
|
WO2004036221A2
(en)
*
|
2002-10-18 |
2004-04-29 |
Wyeth |
Compositions and methods for diagnosing and treating autoimmune disease
|
CA2503491A1
(en)
*
|
2002-10-24 |
2004-05-06 |
Wyeth |
Calcineurin-like human phosphoesterase
|
US7611839B2
(en)
*
|
2002-11-21 |
2009-11-03 |
Wyeth |
Methods for diagnosing RCC and other solid tumors
|
US7297525B2
(en)
|
2002-11-27 |
2007-11-20 |
Wyeth |
Composition employing a novel human kinase
|
WO2004061423A2
(en)
|
2003-01-06 |
2004-07-22 |
Wyeth |
Compositions and methods for diagnosing and treating colon cancers
|
US20040151766A1
(en)
*
|
2003-01-30 |
2004-08-05 |
Monahan Sean D. |
Protein and peptide delivery to mammalian cells in vitro
|
WO2004070062A2
(en)
*
|
2003-02-04 |
2004-08-19 |
Wyeth |
Compositions and methods for diagnosing and treating cancers
|
WO2004076639A2
(en)
*
|
2003-02-26 |
2004-09-10 |
Wyeth |
Use of gene expression profiling in the diagnosis and treatment of lupus nephritis and systemic lupus erythematosus
|
US20040234517A1
(en)
*
|
2003-03-04 |
2004-11-25 |
Wyeth |
Compositions and methods for diagnosing and treating asthma or other allergic or inflammatory diseases
|
CA2521171C
(en)
|
2003-04-03 |
2013-05-28 |
Fluidigm Corp. |
Microfluidic devices and methods of using same
|
WO2004092214A2
(en)
*
|
2003-04-10 |
2004-10-28 |
Aristex |
Affinity purification system using troponin molecules as affinity ligands
|
US20050119210A1
(en)
*
|
2003-05-20 |
2005-06-02 |
Xiaobing Be |
Compositions and methods for diagnosing and treating cancers
|
EP1498445A1
(de)
*
|
2003-07-18 |
2005-01-19 |
DSM IP Assets B.V. |
Wärmestabilisierte Formmasse
|
WO2005020902A2
(en)
*
|
2003-08-21 |
2005-03-10 |
Cytokine Pharmasciences, Inc. |
Compositions and methods for treating and diagnosing irritable bowel syndrome
|
JP4889505B2
(ja)
|
2004-02-02 |
2012-03-07 |
アンブレツクス・インコーポレイテツド |
被修飾されたヒト成長ホルモンポリペプチドおよびこれらの使用
|
WO2005082409A1
(en)
*
|
2004-02-27 |
2005-09-09 |
Pacmab Limited |
Target for b-cell disorders
|
US7384760B2
(en)
*
|
2004-04-30 |
2008-06-10 |
General Atomics |
Methods for assaying inhibitors of S-adenosylhomocysteine (SAH) hydrolase and S-adenosylmethionine (SAM)-dependent methyltransferase
|
JP2008503217A
(ja)
*
|
2004-06-18 |
2008-02-07 |
アンブレツクス・インコーポレイテツド |
新規抗原結合ポリペプチド及びそれらの使用
|
CA2569381A1
(en)
*
|
2004-07-21 |
2006-08-31 |
Ambrx, Inc. |
Biosynthetic polypeptides utilizing non-naturally encoded amino acids
|
WO2009100255A2
(en)
|
2008-02-08 |
2009-08-13 |
Ambrx, Inc. |
Modified leptin polypeptides and their uses
|
AU2005306576A1
(en)
*
|
2004-11-16 |
2006-05-26 |
Sienna Cancer Diagnostics Ltd |
Methods of detecting an analyte in a sample
|
WO2006068802A2
(en)
*
|
2004-12-22 |
2006-06-29 |
Ambrx, Inc. |
COMPOSITIONS OF AMINOACYL-tRNA SYNTHETASE AND USES THEREOF
|
KR101224781B1
(ko)
|
2004-12-22 |
2013-01-21 |
암브룩스, 인코포레이티드 |
비천연적으로 코딩된 아미노산을 포함하는 인간 성장호르몬의 조제물
|
KR20070090023A
(ko)
|
2004-12-22 |
2007-09-04 |
암브룩스, 인코포레이티드 |
변형 인간 성장 호르몬
|
WO2006069246A2
(en)
|
2004-12-22 |
2006-06-29 |
Ambrx, Inc. |
Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
|
JP2008525032A
(ja)
|
2004-12-22 |
2008-07-17 |
アンブレツクス・インコーポレイテツド |
組換えヒト成長ホルモンを発現及び精製するための方法
|
EP1838736B1
(de)
|
2005-01-05 |
2013-03-06 |
Biogen Idec MA Inc. |
Cripto-bindende moleküle
|
EP1861512A4
(de)
|
2005-03-18 |
2009-12-09 |
Fluidigm Corp |
Wärmereaktionsvorrichtung und verwendungsverfahren dafür
|
CA2609205A1
(en)
*
|
2005-06-03 |
2006-12-14 |
Ambrx, Inc. |
Improved human interferon molecules and their uses
|
AU2005335491B2
(en)
*
|
2005-08-18 |
2010-11-25 |
Ambrx, Inc. |
Compositions of tRNA and uses thereof
|
WO2007051077A2
(en)
*
|
2005-10-28 |
2007-05-03 |
The Regents Of The University Of California |
Methods and compounds for lymphoma cell detection and isolation
|
ATE500215T1
(de)
*
|
2005-11-08 |
2011-03-15 |
Ambrx Inc |
Beschleuniger für die modifikation nichtnatürlicher aminosäuren und nichtnatürlicher aminosäurepolypeptide
|
ES2547554T3
(es)
|
2005-11-16 |
2015-10-07 |
Ambrx, Inc. |
Métodos y composiciones que comprenden aminoácidos no naturales
|
KR101423898B1
(ko)
*
|
2005-12-14 |
2014-07-28 |
암브룩스, 인코포레이티드 |
비-천연 아미노산 및 폴리펩티드를 함유하는 조성물, 비-천연 아미노산 및 폴리펩티드를 포함하는 방법, 및 비-천연 아미노산 및 폴리펩티드의 용도
|
EP1981905B1
(de)
|
2006-01-16 |
2016-08-31 |
THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES |
Chlamydia-impfstoff
|
ES2374964T3
(es)
|
2006-01-25 |
2012-02-23 |
Sanofi |
Agentes citotóxicos que comprenden nuevos derivados de tomaimicina.
|
CU23544A1
(es)
*
|
2006-02-28 |
2010-06-17 |
Ct Ingenieria Genetica Biotech |
Antígenos vacunales quiméricos contra el virus de la peste porcina clásica
|
JP5524610B2
(ja)
*
|
2006-04-07 |
2014-06-18 |
ザ リサーチ ファウンデーション オブ ステイト ユニバーシティー オブ ニューヨーク |
トランスコバラミン受容体ポリペプチド、核酸およびその調節因子、ならびに細胞の増殖の調節ならびにガンおよびコバラミン欠損症の処置に使用する関連方法
|
US9044461B2
(en)
|
2006-04-07 |
2015-06-02 |
The Research Foundation Of State University Of New York |
Transcobalamin receptor polypeptides, nucleic acids, and modulators thereof, and related methods of use in modulating cell growth and treating cancer and cobalamin deficiency
|
US20090297530A1
(en)
|
2006-05-22 |
2009-12-03 |
Feng Wang-Johanning |
Herv-k antigens, antibodies, and methods
|
EP1864682A1
(de)
|
2006-06-09 |
2007-12-12 |
Sanofi-Aventis |
Leptomycinderivate
|
CN101541955B
(zh)
*
|
2006-09-08 |
2016-09-28 |
Ambrx公司 |
用于脊椎动物细胞的杂合抑制tRNA
|
PT2064333E
(pt)
*
|
2006-09-08 |
2014-06-09 |
Ambrx Inc |
Supressor híbrido arnt para células de vertebrados
|
EP2069396B1
(de)
|
2006-09-08 |
2015-10-21 |
Ambrx, Inc. |
Modifiziertes polypeptid oder fc-gerüste aus humanem plasma und ihre verwendung
|
WO2008057298A2
(en)
*
|
2006-10-27 |
2008-05-15 |
Wei-Chiang Shen |
Lipidized interferon and uses thereof
|
JP5650406B2
(ja)
|
2007-03-07 |
2015-01-07 |
ユーティーアイ リミテッド パートナーシップ |
自己免疫状態の予防および治療のための組成物および方法
|
PL2068909T3
(pl)
|
2007-03-30 |
2012-09-28 |
Ambrx Inc |
Modyfikowane polipeptydy fgf-21 i ich zastosowanie
|
EP2076533B1
(de)
*
|
2007-05-02 |
2014-10-08 |
Ambrx, Inc. |
Modifizierte interferon-beta-polypeptide und ihre verwendungen
|
US8956825B2
(en)
|
2007-05-24 |
2015-02-17 |
The United States Of America As Represented By The Department Of Veterans Affairs |
Intranuclear protein transduction through a nucleoside salvage pathway
|
AU2008294074B2
(en)
|
2007-08-30 |
2015-01-22 |
Walter And Eliza Hall Institute Of Medical Research |
Dendritic cell marker and uses thereof
|
EP2192922A4
(de)
|
2007-09-17 |
2010-09-29 |
Univ California |
Auf prostatazellen in situ abzielende internalisierende humane monoklonale antikörper
|
US8463365B2
(en)
*
|
2007-09-19 |
2013-06-11 |
Oncofluor, Inc. |
Method for imaging and treating organs and tissues
|
MX349306B
(es)
|
2007-09-21 |
2017-07-19 |
Univ California |
Interferón de objetivo demuestra actividades potentes apoptóticas y antitumorales.
|
US8530628B2
(en)
|
2007-09-28 |
2013-09-10 |
Welcome Receptor Antibodies Pty Ltd |
Diagnosis and treatment of diseased and damaged tissue
|
JP5580205B2
(ja)
|
2007-11-19 |
2014-08-27 |
セレラ コーポレーション |
肺癌マーカーとその使用
|
ES2632504T3
(es)
|
2007-11-20 |
2017-09-13 |
Ambrx, Inc. |
Polipéptidos de insulina modificados y sus usos
|
ES2492670T3
(es)
|
2008-05-27 |
2014-09-10 |
Genzyme Corporation |
Análogos peptídicos de la hormona estimulante de alfa-melanocitos
|
EP3176261A1
(de)
|
2008-06-26 |
2017-06-07 |
aTyr Pharma, Inc. |
Glycyl-trna-synthetasen mit nichtkanonischen biologischen aktivitäten umfassende zusammensetzungen und verfahren
|
RU2011103199A
(ru)
|
2008-06-30 |
2012-08-10 |
Онкотерапи Сайенс, Инк. (Jp) |
Антитела против cdh3, меченные радиоизотопной меткой, и их применение
|
JP5680534B2
(ja)
|
2008-07-23 |
2015-03-04 |
イーライ リリー アンド カンパニー |
修飾されているウシg−csfポリペプチドおよびそれらの使用
|
PE20110832A1
(es)
|
2008-09-26 |
2011-11-24 |
Ambrx Inc |
Polipeptidos de eritropoyetina felina modificados
|
MX348657B
(es)
|
2008-09-26 |
2017-06-21 |
Ambrx Inc |
Microorganismos y vacunas dependientes de replicacion de aminoacidos no naturales.
|
NZ593173A
(en)
|
2008-12-05 |
2012-12-21 |
Abraxis Bioscience Llc |
Osteonectin (Secreted Protein, Acidic, Rich in Cysteines (SPARC)) binding ScFvS
|
ES2626327T3
(es)
|
2009-02-06 |
2017-07-24 |
The Regents Of The University Of California |
Agentes enlazantes de calcio que inducen crecimiento del cabello y/o crecimiento de las uñas
|
WO2010099477A2
(en)
|
2009-02-27 |
2010-09-02 |
Atyr Pharma, Inc. |
Polypeptide structural motifs associated with cell signaling activity
|
EP3255146B1
(de)
|
2009-03-16 |
2019-05-15 |
Pangu Biopharma Limited |
Zusammensetzungen und verfahren mit histidyl-trna-synthetase-spleissvarianten mit nicht-kanonischen biologischen aktivitäten
|
ES2560674T3
(es)
|
2009-03-31 |
2016-02-22 |
Atyr Pharma, Inc. |
Composiciones y procedimientos que comprenden aspartil-ARNt sintetasas con actividades biológicas no canónicas
|
AU2010253863B2
(en)
|
2009-05-28 |
2016-01-28 |
The United States Government As Represented By The Department Of Veterans Affairs |
Amino acid sequences which enhance peptide conjugate solubility
|
EP2448966B1
(de)
|
2009-07-03 |
2018-11-14 |
Avipep Pty Ltd |
Immunkonjugate und verfahren zu ihrer herstellung
|
CA2771336C
(en)
|
2009-09-15 |
2019-11-26 |
The Board Of Trustees Of The Leland Stanford Junior University |
Synergistic anti-cd47 therapy for hematologic cancers
|
CA2783731C
(en)
|
2009-12-11 |
2018-03-27 |
Atyr Pharma, Inc. |
Aminoacyl trna synthetases for modulating inflammation
|
EA201290541A1
(ru)
|
2009-12-21 |
2013-05-30 |
Амбркс, Инк. |
Модифицированные бычьи соматотропиновые полипептиды и их применение
|
CN102666578A
(zh)
|
2009-12-21 |
2012-09-12 |
Ambrx公司 |
经过修饰的猪促生长素多肽和其用途
|
US9315581B2
(en)
|
2009-12-23 |
2016-04-19 |
A Vipep Pty Limited |
Immuno-conjugates and methods for producing them
|
EP3450459B1
(de)
|
2009-12-28 |
2021-05-26 |
OncoTherapy Science, Inc. |
Anti-cdh3-antikörper und verwendungen davon
|
WO2011133948A2
(en)
|
2010-04-22 |
2011-10-27 |
Longevity Biotech, Inc. |
Highly active polypeptides and methods of making and using the same
|
US8871744B2
(en)
|
2010-07-21 |
2014-10-28 |
B & G Partyers, LLC |
Compounds and methods for selectively targeting tumor-associated mucins
|
GB201012410D0
(en)
|
2010-07-23 |
2010-09-08 |
Medical Res Council |
Intracellular immunity
|
AU2011288412A1
(en)
|
2010-08-13 |
2013-02-21 |
Medimmune Limited |
Monomeric polypeptides comprising variant Fc regions and methods of use
|
CA2808596C
(en)
|
2010-08-17 |
2020-12-15 |
Ambrx, Inc. |
Modified relaxin polypeptides and their uses
|
US9567386B2
(en)
|
2010-08-17 |
2017-02-14 |
Ambrx, Inc. |
Therapeutic uses of modified relaxin polypeptides
|
US11246915B2
(en)
|
2010-09-15 |
2022-02-15 |
Applied Molecular Transport Inc. |
Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
|
AU2011302645B2
(en)
|
2010-09-15 |
2015-02-26 |
Applied Molecular Transport, Llc |
Systems and methods of delivery of bioactive agents using bacterial toxin-derived transport sequences
|
AR083006A1
(es)
|
2010-09-23 |
2013-01-23 |
Lilly Co Eli |
Formulaciones para el factor estimulante de colonias de granulocitos (g-csf) bovino y variantes de las mismas
|
EP2621523B1
(de)
|
2010-09-29 |
2017-08-09 |
UTI Limited Partnership |
Verfahren zur behandlung einer autoimmunerkrankung anhand von bioverträglichen bioabsorbierbaren nanokügelchen
|
US9511151B2
(en)
|
2010-11-12 |
2016-12-06 |
Uti Limited Partnership |
Compositions and methods for the prevention and treatment of cancer
|
US8609818B2
(en)
|
2011-03-10 |
2013-12-17 |
Omeros Corporation |
Generation of anti-FN14 monoclonal antibodies by ex-vivo accelerated antibody evolution
|
EP2684048B1
(de)
|
2011-03-11 |
2018-10-03 |
Board of Regents of the University of Nebraska |
Biomarker für koronare herzkrankheit
|
EP2694095B1
(de)
|
2011-04-05 |
2018-03-07 |
Longevity Biotech, Inc. |
Zusammensetzungen mit glukagon-analogen sowie verfahren zu ihrer herstellung und verwendung
|
MX359217B
(es)
|
2011-05-27 |
2018-09-19 |
Ambrx Inc |
Composiciones que contienen, métodos que involucran, y usos de derivados de dolastatina unidos a aminoácidos no naturales.
|
EP2714685B1
(de)
|
2011-05-27 |
2016-10-19 |
Ambrx, Inc. |
Zusammensetzungen, enthaltend mit nichtnatürlichen aminosäuren verknüpfte dolastatin-derivate, sowie verfahren dafür und anwendungen davon
|
MX2013013627A
(es)
|
2011-06-21 |
2014-04-25 |
Oncofactor Corp |
Composiciones y metodos para la terapia y diagnostico de cancer.
|
HUE029855T2
(en)
|
2011-07-05 |
2017-04-28 |
Bioasis Technologies Inc |
p97 antibody conjugates
|
WO2013012733A1
(en)
|
2011-07-15 |
2013-01-24 |
Biogen Idec Ma Inc. |
Heterodimeric fc regions, binding molecules comprising same, and methods relating thereto
|
US9120858B2
(en)
|
2011-07-22 |
2015-09-01 |
The Research Foundation Of State University Of New York |
Antibodies to the B12-transcobalamin receptor
|
JP5944994B2
(ja)
|
2011-08-12 |
2016-07-05 |
オメロス コーポレーション |
抗fzd10モノクローナル抗体およびそれらの使用方法
|
ES2682254T3
(es)
|
2011-08-18 |
2018-09-19 |
Affinity Biosciences Pty Ltd |
Polipéptidos solubles
|
WO2013106577A2
(en)
|
2012-01-10 |
2013-07-18 |
Biogen Idec Ma Inc. |
Enhancement of transport of therapeutic molecules across the blood brain barrier
|
GB201202268D0
(en)
|
2012-02-09 |
2012-03-28 |
Medical Res Council |
Intracellular immunity
|
DK2822575T3
(da)
|
2012-03-03 |
2020-06-15 |
Immungene Inc |
Manipulerede, muterede antistof-interferon-fusionsmolekyler
|
US10988516B2
(en)
|
2012-03-26 |
2021-04-27 |
Uti Limited Partnership |
Methods and compositions for treating inflammation
|
SG11201408153YA
(en)
|
2012-06-07 |
2015-01-29 |
Ambrx Inc |
Prostate-specific membrane antigen antibody drug conjugates
|
JP6498600B2
(ja)
|
2012-06-08 |
2019-04-10 |
ストロ バイオファーマ インコーポレーテッド |
部位特異的な非天然アミノ酸残基を含む抗体、その調製方法、及びその使用方法
|
WO2013188740A1
(en)
|
2012-06-14 |
2013-12-19 |
Ambrx, Inc. |
Anti-psma antibodies conjugated to nuclear receptor ligand polypeptides
|
ES2712648T3
(es)
|
2012-06-19 |
2019-05-14 |
Ambrx Inc |
Conjugados de fármaco de anticuerpo anti-CD70
|
US9732161B2
(en)
|
2012-06-26 |
2017-08-15 |
Sutro Biopharma, Inc. |
Modified Fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use
|
CA2880162C
(en)
|
2012-07-31 |
2023-04-04 |
Bioasis Technologies, Inc. |
Dephosphorylated lysosomal storage disease proteins and methods of use thereof
|
JP2015529655A
(ja)
|
2012-08-02 |
2015-10-08 |
ステルス ペプチドズ インターナショナル インコーポレイテッド |
アテローム性硬化症の処置方法
|
CN104981254B
(zh)
|
2012-08-31 |
2018-05-22 |
苏特罗生物制药公司 |
含有叠氮基的经修饰的氨基酸
|
US9603948B2
(en)
|
2012-10-11 |
2017-03-28 |
Uti Limited Partnership |
Methods and compositions for treating multiple sclerosis and related disorders
|
WO2014160438A1
(en)
|
2013-03-13 |
2014-10-02 |
Bioasis Technologies Inc. |
Fragments of p97 and uses thereof
|
WO2014145718A2
(en)
|
2013-03-15 |
2014-09-18 |
Longevity Biotech, Inc. |
Peptides comprising non-natural amino acids and methods of making and using the same
|
EP3019522B1
(de)
|
2013-07-10 |
2017-12-13 |
Sutro Biopharma, Inc. |
Antikörper mit mehreren ortsspezifischen nichtnatürlichen aminosäureresten, verfahren zu deren herstellung und verfahren zu deren verwendung
|
AU2014312190A1
(en)
|
2013-08-28 |
2016-02-18 |
Bioasis Technologies Inc. |
CNS-targeted conjugates of antibodies
|
US11559580B1
(en)
|
2013-09-17 |
2023-01-24 |
Blaze Bioscience, Inc. |
Tissue-homing peptide conjugates and methods of use thereof
|
US9840493B2
(en)
|
2013-10-11 |
2017-12-12 |
Sutro Biopharma, Inc. |
Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
|
US10519247B2
(en)
|
2013-11-01 |
2019-12-31 |
Board Of Regents,The University Of Texas System |
Targeting HER2 and HER3 with bispecific antibodies in cancerous cells
|
MX2016005822A
(es)
|
2013-11-04 |
2016-12-02 |
Uti Limited Partnership |
Metodos y composiciones para inmunoterpia sostenida.
|
US11046763B2
(en)
|
2014-01-08 |
2021-06-29 |
The Board Of Trustees Of The Leland Stanford Junior University |
Targeted therapy for small cell lung cancer
|
AU2015255834B2
(en)
|
2014-05-07 |
2020-05-21 |
Applied Molecular Transport Llc |
Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
|
WO2015183988A1
(en)
|
2014-05-28 |
2015-12-03 |
Stealth Peptides International, Inc. |
Therapeutic compositions including therapeutic small molecules and uses thereof
|
EP3148565A4
(de)
|
2014-05-28 |
2018-06-06 |
Stealth Biotherapeutics Corp |
Therapeutische zusammensetzungen mit frataxin, lactoferrin, sowie mitochondrialen energieerzeugungsenzymen und verwendungen davon
|
CA2944085C
(en)
|
2014-09-16 |
2018-04-10 |
Ease Charm Limited |
Anti-egfr antibody and uses of same
|
JP6702962B2
(ja)
|
2014-10-24 |
2020-06-03 |
ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company |
改変fgf−21ポリペプチドおよびその使用
|
EP3215537B1
(de)
|
2014-11-05 |
2022-01-05 |
Nanyang Technological University |
Stabilisierte und autonome vh-domäne eines antikörpers
|
EP3265474A1
(de)
|
2015-03-05 |
2018-01-10 |
Sirenas LLC |
Cyclische peptidanaloga und konjugate davon
|
CA2984485A1
(en)
|
2015-05-06 |
2016-12-15 |
Uti Limited Partnership |
Nanoparticle compositions for sustained therapy
|
US10478510B2
(en)
|
2015-07-16 |
2019-11-19 |
Case Western Resrve University |
Plant virus particles for delivery of antimitotic agents
|
EP3370771A4
(de)
|
2015-11-03 |
2019-06-19 |
Ambrx, Inc. |
Anti-cd3-folat-konjugate und deren verwendungen
|
CA3006759A1
(en)
|
2015-11-30 |
2017-06-08 |
The Regents Of The University Of California |
Tumor-specific payload delivery and immune activation using a human antibody targeting a highly specific tumor cell surface antigen
|
MX2018009085A
(es)
|
2016-01-27 |
2019-05-09 |
Sutro Biopharma Inc |
Conjugados de anticuerpos anti-cd74, composiciones que comprenden conjugados de anticuerpos anti-cd74 y metodos de uso de congujados de anticuerpos anti-cd74.
|
US20190161523A1
(en)
|
2016-04-12 |
2019-05-30 |
Blaze Bioscience, Inc. |
Methods of treatment using chlorotoxin conjugates
|
US20190282661A1
(en)
|
2016-04-15 |
2019-09-19 |
Blaze Bioscience, Inc. |
Methods of treating breast cancer
|
WO2017218824A1
(en)
|
2016-06-15 |
2017-12-21 |
Yale University |
Anti-guanosine antibody as a molecular delivery vehicle
|
US11254705B2
(en)
|
2016-09-02 |
2022-02-22 |
Sirenas Llc |
Cyclic peptide analogs and conjugates thereof
|
US11434301B2
(en)
|
2016-11-11 |
2022-09-06 |
The Regents Of The University Of California |
Anti-CD46 antibodies and methods of use
|
ES2928184T3
(es)
|
2016-12-12 |
2022-11-16 |
Cepheid |
Inmuno-PCR integrado y análisis de ácidos nucleicos en un cartucho de reacción automatizado
|
EP3554638B1
(de)
|
2016-12-19 |
2022-02-02 |
Morehouse School of Medicine |
Zusammensetzungen und verfahren zur behandlung von krankheiten durch hemmung der exosomenfreisetzung
|
US10800817B2
(en)
|
2016-12-19 |
2020-10-13 |
Morehouse School Of Medicine |
Compositions and methods for treating diseases by inhibiting exosome release
|
MX2019008056A
(es)
|
2017-01-05 |
2019-11-21 |
Univ California |
Agonistas del receptor pac1 (maxcaps) y usos de estos.
|
CN110637027A
(zh)
|
2017-02-08 |
2019-12-31 |
百时美施贵宝公司 |
包含药代动力学增强子的修饰的松弛素多肽及其用途
|
US20200207859A1
(en)
|
2017-07-26 |
2020-07-02 |
Sutro Biopharma, Inc. |
Methods of using anti-cd74 antibodies and antibody conjugates in treatment of t-cell lymphoma
|
BR112020005212A2
(pt)
|
2017-09-18 |
2020-09-15 |
Sutro Biopharma, Inc. |
conjugado de anticorpo, kit, composição farmacêutica, e, métodos de tratamento ou prevenção e de diagnóstico de uma doença ou condição.
|
US20210054102A1
(en)
|
2018-02-01 |
2021-02-25 |
Yale University |
Compositions and methods for enhancing nuclear translocation
|
CA3093386A1
(en)
|
2018-03-08 |
2019-09-12 |
Applied Molecular Transport Inc. |
Toxin-derived delivery constructs for oral delivery
|
ES2920428T3
(es)
|
2018-03-08 |
2022-08-03 |
Applied Molecular Transport Inc |
Constructos de administración derivados de toxinas para la administración oral
|
AU2019245444A1
(en)
|
2018-03-29 |
2020-10-01 |
Ambrx, Inc. |
Humanized anti-prostate-specific membrane antigen (PSMA) antibody drug conjugates
|
EP3813867A1
(de)
|
2018-07-22 |
2021-05-05 |
Bioasis Technologies Inc. |
Behandlung von lymphatischen metastasen
|
AU2019327456A1
(en)
|
2018-08-28 |
2021-04-15 |
Ambrx, Inc. |
anti-CD3 antibody folate bioconjugates and their uses
|
PL3849614T3
(pl)
|
2018-09-11 |
2024-04-22 |
Ambrx, Inc. |
Koniugaty polipeptydu interleukiny-2 i ich zastosowania
|
JP2022500454A
(ja)
|
2018-09-17 |
2022-01-04 |
ストロ バイオファーマ インコーポレーテッド |
抗葉酸受容体抗体コンジュゲートによる併用療法
|
JP2022512746A
(ja)
|
2018-10-19 |
2022-02-07 |
アンブルックス,インコーポレイテッド |
インターロイキン-10ポリペプチド複合体、その二量体、およびそれらの使用
|
CA3119179A1
(en)
|
2018-11-07 |
2020-05-14 |
Applied Molecular Transport Inc. |
Cholix-derived carriers for oral delivery of heterologous payload
|
WO2020168017A1
(en)
|
2019-02-12 |
2020-08-20 |
Ambrx, Inc. |
Compositions containing, methods and uses of antibody-tlr agonist conjugates
|
WO2020227105A1
(en)
|
2019-05-03 |
2020-11-12 |
Sutro Biopharma, Inc. |
Anti-bcma antibody conjugates
|
JP2022536490A
(ja)
|
2019-06-10 |
2022-08-17 |
ストロ バイオファーマ インコーポレーテッド |
5H-ピロロ[3,2-d]ピリミジン-2,4-ジアミノ化合物およびその抗体コンジュゲート
|
EP3983410A1
(de)
|
2019-06-17 |
2022-04-20 |
Sutro Biopharma, Inc. |
1-(4-(aminomethyl)benzyl)-2-butyl-2h-pyrazolo[3,4-c]quinolin-4-aminderivate und verwandte verbindungen als toll-like- rezeptor (tlr) 7/8-agonisten sowie antikörper-wirkstoff-konjugate davon zur verwendung in der krebstherapie und -diagnose
|
MX2022001975A
(es)
|
2019-08-16 |
2022-03-11 |
Applied Molecular Transport Inc |
Composiciones, formulaciones y produccion y purificacion de interleucinas.
|
WO2021173889A1
(en)
|
2020-02-26 |
2021-09-02 |
Ambrx, Inc. |
Uses of anti-cd3 antibody folate bioconjugates
|
JP2023517595A
(ja)
|
2020-03-11 |
2023-04-26 |
アンブルックス,インコーポレイテッド |
インターロイキン-2ポリペプチド結合物およびその使用方法
|
US20210355468A1
(en)
|
2020-05-18 |
2021-11-18 |
Bioasis Technologies, Inc. |
Compositions and methods for treating lewy body dementia
|
US20210393787A1
(en)
|
2020-06-17 |
2021-12-23 |
Bioasis Technologies, Inc. |
Compositions and methods for treating frontotemporal dementia
|
WO2022013613A2
(en)
|
2020-07-17 |
2022-01-20 |
Onena Medicines S.L. |
Antibodies against lefty proteins
|
MX2023001625A
(es)
|
2020-08-07 |
2023-05-16 |
Fortis Therapeutics Inc |
Inmunoconjugados que se dirigen a cd46 y metodos de uso de los mismos.
|
US20230302150A1
(en)
|
2020-08-20 |
2023-09-28 |
Ambrx, Inc. |
Antibody-tlr agonist conjugates, methods and uses thereof
|
WO2022103983A2
(en)
|
2020-11-11 |
2022-05-19 |
Sutro Biopharma, Inc. |
Fluorenylmethyloxycarbonyl and fluorenylmethylaminocarbonyl compounds, protein conjugates thereof, and methods for their use
|
KR20240004342A
(ko)
|
2021-04-03 |
2024-01-11 |
암브룩스, 인코포레이티드 |
항-her2 항체-약물 접합체 및 이의 용도
|
US11931420B2
(en)
|
2021-04-30 |
2024-03-19 |
Celgene Corporation |
Combination therapies using an anti-BCMA antibody drug conjugate (ADC) in combination with a gamma secretase inhibitor (GSI)
|
US11180534B1
(en)
|
2021-06-04 |
2021-11-23 |
Morehouse School Of Medicine |
Compositions and methods for treating SARS-CoV-2 infections
|
WO2023010060A2
(en)
|
2021-07-27 |
2023-02-02 |
Novab, Inc. |
Engineered vlrb antibodies with immune effector functions
|
WO2023056450A1
(en)
|
2021-09-30 |
2023-04-06 |
Yale University |
Compositions and methods for the treatment of autosomal dominant polycystic kidney disease and other diseases having upregulated mtor activity
|
WO2024006542A1
(en)
|
2022-06-30 |
2024-01-04 |
Sutro Biopharma, Inc. |
Anti-ror1 antibodies and antibody conjugates, compositions comprising anti-ror1 antibodies or antibody conjugates, and methods of making and using anti-ror1 antibodies and antibody conjugates
|
WO2024050524A1
(en)
|
2022-09-01 |
2024-03-07 |
University Of Georgia Research Foundation, Inc. |
Compositions and methods for directing apolipoprotein l1 to induce mammalian cell death
|
WO2024064752A2
(en)
|
2022-09-20 |
2024-03-28 |
Yale University |
Compositions of wet adhesives derived from vibrio cholerae biofilm adhesins and methods thereof
|
WO2024077277A1
(en)
|
2022-10-07 |
2024-04-11 |
Ambrx, Inc. |
Drug linkers and antibody conjugates thereof
|